Risk Factors for Disseminated Coccidioidomycosis, United States

Of 150,000 new coccidioidomycosis infections that occur annually in the United States, ≈1% disseminate; one third of those cases are fatal. Immunocompromised hosts have higher rates of dissemination. We identified 8 patients with disseminated coccidioidomycosis who had defects in the interleukin-12/interferon-γ and STAT3 axes, indicating that these are critical host defense pathways.

Coccidioidomycosis is acquired by inhaling spores of *Coccidioides immitis*. The Centers for Disease Control and Prevention reported 22,401 cases (42.6 cases/100,000 population) in 2011, an increase from 2,265 cases (5.3/100,000) reported in 1998 (1). Although Coccidioides infection usually produces little illness and results in lifelong immunity, 25%–30% of infections result in protracted but self-limited illness; <1% are complicated by dissemination, which is serious and sometimes fatal (2–4). Diagnosis and treatment remain challenging, especially in persons with disseminated, severe, or chronic disease, where host immunity plays an important role.

1Current affiliation: Yale–New Haven Hospital, New Haven, Connecticut, USA.
During January–March 2014, we reviewed risk factors for dissemination and summarized all coccidioidomycosis cases in patients with primary immunodeficiency (PID). These cases highlight the importance of the interleukin (IL)–12/interferon (IFN)–γ and signal transducer and activator of transcription 3 (STAT3) pathways in host defense. Dissemination of this typically self-limited pathogen should prompt consideration of underlying host genetic factors.

Literature Review
Our systematic literature search resulted in 370 case reports of disseminated coccidioidomycosis (DC) published during 1975–2014 (online Technical Appendix, https://www.cdc.gov/EID/article/23/2/16-0505-Techapp1.pdf). DC was defined as a positive culture or histologic finding from a nonpulmonary site. For comparative purposes, patients were further classified by exogenous immunosuppression, pregnancy, or 1 versus >2 extrapulmonary affected sites.

How the host responds to and contains coccidioidomycosis is unclear, but dissemination occurs in 30%–50% of immunosuppressed hosts. Dissemination can be single-site or multisite, is associated with more severe outcomes than disease limited to the respiratory tract, and requires prolonged treatment (4). Literature review confirms critical interactions of *Coccidioides* spp. with race/ethnicity, sex, pregnancy, and immune status (Table 1).

The rate of DC is higher for pregnant woman than for the general population (5,6). We found dissemination to the nervous system reported in 37% of pregnant women, approximately one third of whom died (https://www.cdc.gov/EID/article/23/2/16-0505-Techapp1.pdf). Of total deaths, 75% occurred among women during their third trimester; fetal or infant death occurred in 40% of reported cases. Although one third of pregnant women affected were black, survival did not differ by race.

Despite overall improved survival, immunocompromised persons remain at high risk for fatal DC; the crude mortality rate (CMR) was ≈50% for persons immunocompromised by HIV, cancer, organ transplantation, antia graft rejection medications, antiinflammatory biologicals, or chemotherapy (https://www.cdc.gov/EID/article/23/2/16-0505-Techapp1.pdf). CMRs were lower, but still substantial, for patients receiving steroids (https://www.niaid.nih.gov/sites/default/files/HollandTechnicalAppendix.docx). In HIV-infected exogenously immunocompromised patients, coccidioidomycosis was similar to that in persons without HIV/AIDS. CMRs were lower for persons who were able to stop exogenous immunosuppression. Patients with exogenous immunosuppression were 37% white, 20% Hispanic, and 11% black (https://www.niaid.nih.gov/sites/default/files/HollandTechnicalAppendix.docx), similar to the racial/ethnic distribution in DC-endemic areas (California, Arizona: 48% white, 34% Hispanic, 6% black) (7,8). However, these racial/ethnic differences should be interpreted cautiously because race/ethnicity data were unavailable for 24% of patients with exogenous immunosuppression. Regardless of age, immunosuppressed patients were substantially more likely to have extrapulmonary dissemination, require hospitalization, have progressive infection, or die of coccidioidomycosis.

Most (84%) patients with multisite infection were male, and the number of blacks was double that of any other race (https://www.cdc.gov/EID/article/23/2/16-0505-Techapp1.pdf). Additionally, osteomyelitis was more common among blacks (82%) than whites (29%); central nervous system (CNS) infection was more common among whites (59%) than blacks (13%). Hispanics and Asians also had higher rates of osteomyelitis (69% and 60%, respectively) and lower rates of CNS dissemination (38% and 13%, respectively) than whites (https://www.cdc.gov/EID/article/23/2/16-0505-Techapp1.pdf). In contrast, among patients with exogenous immunosuppression, differences in rates of osteomyelitis and CNS infections by race were much smaller (44% of blacks with osteomyelitis vs. 24% of whites and 33% of blacks with CNS infection vs. 21% of whites). These data suggest that different immunologic factors that track with race might variably control susceptibility to DC, osteomyelitis, and CNS disease. However, exogenous immunosuppression apparently overrides these racial/ethnic variations.

Consistent with the demographic characteristics of patients with multisite disease, 83% of those with single-site infection were male (https://www.cdc.gov/EID/article/23/2/16-0505-Techapp1.pdf).

<table>
<thead>
<tr>
<th>Predispotion/no. sites affected</th>
<th>Sex, no.</th>
<th>Race/ethnicity, %</th>
<th>Age, y, median (range)</th>
<th>Site of disease, %</th>
<th>Survival, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy, N = 52</td>
<td>M, 59; F, 19</td>
<td>Black, 19; white, 14; Hispanic, 11; Asian 3</td>
<td>27 (17–38)</td>
<td>CNS, 18; bone, 5</td>
<td>42</td>
</tr>
<tr>
<td>Immunocompromise,† N = 79</td>
<td>M, 84; F, 16</td>
<td>Black, 39; white, 17; Hispanic, 13; Asian, 15</td>
<td>36 (1–84)</td>
<td>CNS, 29; bone, 62</td>
<td>72</td>
</tr>
<tr>
<td>Multisite dissemination, N = 100</td>
<td>M, 115; F, 24</td>
<td>Black, 32; white, 21; Hispanic, 9; Asian, 17</td>
<td>33 (1–73)</td>
<td>CNS, 9; bone, 50</td>
<td>99</td>
</tr>
</tbody>
</table>

*CNS, central nervous system.
†Oncologic, n = 8; HIV, n = 12; transplant, n = 24; steroids/immune-modulation, n = 35.
Overall, blacks had more single-site osteomyelitis than whites (64% vs. 41%), and whites had more CNS infection than blacks (17% vs. 2%). Thus, despite the lower CMR in single-site disease, racial/ethnic differences in infection site were largely consistent between those with single-site and multisite infection.

Single-site and multisite disease accounted for 86% of extrapulmonary Coccidioides infections in blacks and 91% in Asians but for only 56% in whites and 52% in Hispanics. Furthermore, blacks accounted for approximately one third of single-site and multisite infections despite constituting only 6% of the population in coccidioidomycosis-endemic areas. In contrast, only 10% of patients with single-site and multisite disease were Hispanic, even though Hispanics accounted for 35% of the general population in those areas (7). The more population-consistent number of blacks with DC among exogenously immunosuppressed persons and the blunting of racial/ethnic differences with exogenous immunosuppression suggest that exogenous immunosuppression overwhets intrinsic racial/ethnic variations in host defense. Interpretation of these differences is limited by self-identified race/ethnicity, an imprecise surrogate for ancestral genetic origins. Future studies using established ancestral markers will help solidify associations between coccidioidomycosis infection and race/ethnicity.

We identified 8 cases of proven PID with DC (Table 2). Mutations in the IL-12/IFN-γ or STAT3 pathways were diagnosed in PID patients (online Technical Appendix Figure); these patients were younger and more racially/ethnically diverse than immunosuppressed single-site and multisite infected groups. All patients with discrete immune defects had prolonged, refractory infection; some were controlled with exogenous IFN-γ. Of the 8 patients, 3 had no relevant prior medical histories, suggesting that discrete mutations in these pathways might go unrecognized until DC develops.

In Coccidioides-susceptible mice, exogenous IL-12 is protective, whereas disease in resistant strains is exacerbated by its neutralization (13). In vitro, human macrophage killing of phagocytosed Coccidioides depends on IL-12/IFN-γ signaling (14). Furthermore, peripheral blood mononuclear cells from nonimmune (delayed-type hypersensitivity-negative) donors produce significantly less IFN-γ in response to Coccidioides antigens than do such cells from immune (delayed-type hypersensitivity-positive) donors. In vivo, 3 patients with DC improved substantially after therapy with IFN-γ. Immune function studies in 2 of those patients showed blunted IFN-γ-mediated responses (15).

The involvement of STAT3 in resistance to Coccidioides infection is complex. STAT3 is a critical mediator of IL-23 signaling, a cytokine involved in producing IFN-γ, IL-12, and IL-17, all of which are required for immunity to extrapulmonary Coccidioides infection. STAT3 signaling (14). Furthermore, human macrophage killing of phagocytosed Coccidioides depends on IL-12/IFN-γ signaling (14). Furthermore, peripheral blood mononuclear cells from nonimmune (delayed-type hypersensitivity-negative) donors produce significantly less IFN-γ in response to Coccidioides antigens than do such cells from immune (delayed-type hypersensitivity-positive) donors. In vivo, 3 patients with DC improved substantially after therapy with IFN-γ. Immune function studies in 2 of those patients showed blunted IFN-γ-mediated responses (15).

The involvement of STAT3 in resistance to Coccidioides infection is complex. STAT3 is a critical mediator of IL-23 signaling, a cytokine involved in producing IFN-γ, IL-12, and IL-17, all of which are required for immunity to

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Age, y/sex</th>
<th>Race/ethnicity</th>
<th>Medical history</th>
<th>Extrapulmonary disease</th>
<th>Relapse</th>
<th>Method of diagnosis</th>
<th>Genetic findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4/F</td>
<td>White</td>
<td>HIES, recurrent pneumonia and otitis, skin infections, eczema, thrust</td>
<td>Meningitis</td>
<td>No</td>
<td>BAL/CSF cultures</td>
<td>STAT3: heterozygous (c.2137G&gt;A)</td>
</tr>
<tr>
<td>2 (9)</td>
<td>17/F</td>
<td>Not reported</td>
<td>HIES, Staphylococcus aureus skin and soft tissue infections, recurrent sinus infections, pneumonia</td>
<td>Meningitis, cerebral abscess</td>
<td>No</td>
<td>Coccidioides Ab, CSF culture</td>
<td>STAT3: heterozygous (p.T412S)</td>
</tr>
<tr>
<td>3 (10)</td>
<td>11/M</td>
<td>White</td>
<td>11 mo: Mycobacterium chelonae pneumonia 22 y; disseminated M. kansasi</td>
<td>Osteomyelitis, lymphadenitis</td>
<td>Yes</td>
<td>Coccidioides Ab level, lymph node biopsy</td>
<td>IFN-γR1: deficiency (c.816del4fs)</td>
</tr>
<tr>
<td>4 (11)†</td>
<td>22/F</td>
<td>Palestinian</td>
<td>11 y: Salmonella serogroup D lymphadenitis</td>
<td>Diffuse lymphadenitis</td>
<td>Yes</td>
<td>Coccidioides IgM and IgG, lymph node biopsy</td>
<td>IL-12R1: homozygous (p.C186Y)</td>
</tr>
<tr>
<td>5 (11)</td>
<td>6/M</td>
<td>Palestinian</td>
<td>No other significant history</td>
<td>Osteomyelitis, lymphadenitis, nasal lesion,</td>
<td>Yes</td>
<td>Lymph node, nasal lesion, bone biopsies</td>
<td>IL-12R1: homozygous (p.C186Y)</td>
</tr>
<tr>
<td>6</td>
<td>15/M</td>
<td>Black</td>
<td>No other significant history</td>
<td>Osteomyelitis, soft tissue</td>
<td>Yes</td>
<td>BAL cultures, bone and soft biopsies</td>
<td>IL-12R1: homozygous (p.C101Y)</td>
</tr>
<tr>
<td>7 (12)</td>
<td>17/F</td>
<td>Hispanic</td>
<td>14 y: extensive, persistent tinea capitis and kerion caused by Trichophyton tonsurans</td>
<td>Osteomyelitis, soft tissue, cutaneous lesions</td>
<td>Yes</td>
<td>Coccidioides Ab, skin biopsy</td>
<td>STAT1: gain of function mutation (p.E353K)</td>
</tr>
<tr>
<td>8 (12)</td>
<td>9.5/F</td>
<td>White</td>
<td>No other significant history</td>
<td>Osteomyelitis, cerebral lesions, intrathoracic lymphadenitis</td>
<td>Yes</td>
<td>Coccidioides Ab</td>
<td>STAT1: gain of function mutation (p.A267V)</td>
</tr>
</tbody>
</table>

*Ab, antibody; BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; HIES, hyperimmunoglobulin E (Job’s) syndrome; ref, reference. †Patients 4 and 5 are siblings, and their parents are first cousins.
Coccidioides in vivo. It also might be involved downstream of dectin-1, which is required for resistance to Coccidioides in mice and induces the phosphorylation of STAT3.

Conclusions

Risk factors for DC include exogenous immunosuppression (steroids and biologicals), pregnancy, race/ethnicity, and discrete genetic defects. Although racial/ethnic associations with DC were evident in patients without known underlying risks, they were submerged by exogenous immunosuppression.

Functional and genetic studies indicate that the IL-12/IFN-γ axis and STAT3-mediated immunity are central to protection against Coccidioides. We identified mutations affecting these pathways in 8 patients with especially severe or refractory DC, some of whom responded to IFN-γ therapy. Younger patients with severe DC or patients whose illness relapses should be considered for genetic screening for discrete primary immune defects. The discrete defects demonstrated here clearly do not account for all occurrences of coccidioidomycosis in the general population but highlight the importance and nature of genetic control.

Coccidioidomycosis is distinguished by its geography and relative virulence in many persons who otherwise appear immunologically competent. Because most persons in whom DC develops are previously healthy, Coccidioides most likely exploits a very narrow vulnerability. The demonstration that DC has an underlying genetic predisposition indicates that the advent of newer genetic techniques, such as whole exome/genome sequencing, will inevitably identify coccidioidomycosis-specific genetic factors. These, in turn, should enable us to better understand, preempt and treat coccidioidomycosis.

This study was funded in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), USA.

C.D.O. was funded through the NIH Medical Research Scholars Program, a public-private partnership supported jointly by NIH and generous contributions to the Foundation for the NIH from Pfizer Inc., The Doris Duke Charitable Foundation, The Alexandria Real Estate Equities, Inc. and Mr. and Mrs. Joel S. Marcus, and the Howard Hughes Medical Institute, as well as other private donors. For a complete list, visit the Foundation website (http://fnih.org/work/education-training-0/medical-research-scholars-program).

Dr. Odio completed this work while she was a medical student at the Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA. She now an internal medicine resident at Yale–New Haven Hospital. Her research interests include infectious diseases, immunology, and host-pathogen interactions.

References


Address for correspondence: Steven M. Holland, National Institutes of Health, Bldg 10, Rm 11N248, MSC 1960, Bethesda, MD 20892-1960, USA; email: smih@nih.gov